CA2114300C - Quinoline or quinazoline derivatives, their production and use - Google Patents

Quinoline or quinazoline derivatives, their production and use Download PDF

Info

Publication number
CA2114300C
CA2114300C CA002114300A CA2114300A CA2114300C CA 2114300 C CA2114300 C CA 2114300C CA 002114300 A CA002114300 A CA 002114300A CA 2114300 A CA2114300 A CA 2114300A CA 2114300 C CA2114300 C CA 2114300C
Authority
CA
Canada
Prior art keywords
group
ring
triazol
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002114300A
Other languages
English (en)
French (fr)
Other versions
CA2114300A1 (en
Inventor
Takashi Sohda
Haruhiko Makino
Atsuo Baba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CA2114300A1 publication Critical patent/CA2114300A1/en
Application granted granted Critical
Publication of CA2114300C publication Critical patent/CA2114300C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CA002114300A 1993-01-28 1994-01-26 Quinoline or quinazoline derivatives, their production and use Expired - Fee Related CA2114300C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1262893 1993-01-28
JP012628/1993 1993-01-28
JP206128/1993 1993-08-20
JP20612893 1993-08-20

Publications (2)

Publication Number Publication Date
CA2114300A1 CA2114300A1 (en) 1994-07-29
CA2114300C true CA2114300C (en) 2000-10-17

Family

ID=26348258

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002114300A Expired - Fee Related CA2114300C (en) 1993-01-28 1994-01-26 Quinoline or quinazoline derivatives, their production and use

Country Status (15)

Country Link
US (3) US5436247A (OSRAM)
EP (1) EP0608870B1 (OSRAM)
KR (1) KR100224135B1 (OSRAM)
CN (1) CN1041520C (OSRAM)
AT (1) ATE205199T1 (OSRAM)
AU (1) AU673213B2 (OSRAM)
CA (1) CA2114300C (OSRAM)
DE (1) DE69428142T2 (OSRAM)
FI (1) FI940414A7 (OSRAM)
HU (1) HU217907B (OSRAM)
NO (2) NO306992B1 (OSRAM)
NZ (1) NZ250761A (OSRAM)
RU (1) RU2132330C1 (OSRAM)
SG (1) SG50546A1 (OSRAM)
TW (1) TW256832B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW232013B (OSRAM) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
NO306992B1 (no) * 1993-01-28 2000-01-24 Takeda Chemical Industries Ltd Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
ATE188377T1 (de) * 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
EP0749426A1 (en) * 1994-03-08 1996-12-27 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
US5641788A (en) * 1994-06-07 1997-06-24 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them
CA2193110C (en) * 1994-06-24 2001-09-04 Takeda Chemical Industries, Ltd. Processes for production of quinoline or quinazoline derivatives and intermediates therefor
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
HUP9801628A2 (hu) * 1995-04-28 1999-01-28 Takeda Chemical Industries, Ltd. Artritisz elleni gyógyászati készítmények
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CZ296845B6 (cs) * 1997-05-28 2006-07-12 Aventis Pharmaceuticals Inc. Derivát chinolinu a chinoxalinu, farmaceutický prostredek obsahující tento derivát a pouzití
DE19728835C1 (de) * 1997-07-05 1998-09-10 Ruetgers Vft Ag Verfahren zur Reinigung von Chinaldin
JP4059671B2 (ja) * 2000-01-17 2008-03-12 帝人株式会社 ベンズイミダゾール誘導体
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
RU2183116C1 (ru) * 2001-07-10 2002-06-10 Жаров Олег Владимирович Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
ES2285971T3 (es) * 2002-07-15 2008-11-16 Scinopharm Taiwan, Ltd. Procedimiento para la preparacion de imidazo(1,2-a)piridin-3-acetamidas.
CA2505239A1 (en) * 2002-11-06 2004-05-21 Kensuke Nagashima Process for producing quinolinecarbaldehyde
EP1618094B1 (en) * 2003-04-30 2007-09-05 The Institutes for Pharmaceutical Discovery, LLC Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US7937406B2 (en) * 2003-09-11 2011-05-03 Oracle America, Inc. Mechanism for automatically establishing a resource grid
CN101068788A (zh) * 2004-11-01 2007-11-07 弗·哈夫曼-拉罗切有限公司 作为gabab受体的别构增强剂的喹啉化合物
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
CA2645641A1 (en) * 2006-03-21 2007-09-27 Alza Corporation Hydratable polymeric ester matrix for drug electrotransport
CA2781865A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
EP2640715A1 (en) * 2010-11-17 2013-09-25 Amgen Inc. Quinoline derivatives as pik3 inhibitors
RU2648247C2 (ru) * 2012-08-24 2018-03-23 Ф. Хоффманн-Ля Рош Аг Бициклические производные пиридина, полезные в качестве ингибитора белков, связывающих жирные кислоты (FABP) 4 и/или 5

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US5084462A (en) * 1988-04-26 1992-01-28 The Du Pont Merck Pharmaceutical Company 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
TW232013B (OSRAM) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
NO306992B1 (no) * 1993-01-28 2000-01-24 Takeda Chemical Industries Ltd Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
CA2193110C (en) * 1994-06-24 2001-09-04 Takeda Chemical Industries, Ltd. Processes for production of quinoline or quinazoline derivatives and intermediates therefor

Also Published As

Publication number Publication date
NZ250761A (en) 1995-03-28
FI940414A0 (fi) 1994-01-27
AU673213B2 (en) 1996-10-31
SG50546A1 (en) 1998-07-20
NO940245D0 (no) 1994-01-24
CN1105363A (zh) 1995-07-19
DE69428142T2 (de) 2002-07-04
US5770602A (en) 1998-06-23
FI940414L (fi) 1994-07-29
AU5474294A (en) 1994-08-04
EP0608870A1 (en) 1994-08-03
DE69428142D1 (de) 2001-10-11
HU9400250D0 (en) 1994-05-30
KR100224135B1 (ko) 1999-10-15
CA2114300A1 (en) 1994-07-29
US5932592A (en) 1999-08-03
EP0608870B1 (en) 2001-09-05
NO306992B1 (no) 2000-01-24
KR940018381A (ko) 1994-08-16
CN1041520C (zh) 1999-01-06
RU2132330C1 (ru) 1999-06-27
HU217907B (hu) 2000-05-28
NO940245L (no) 1994-07-29
HUT70194A (en) 1995-09-28
FI940414A7 (fi) 1994-07-29
ATE205199T1 (de) 2001-09-15
TW256832B (OSRAM) 1995-09-11
US5436247A (en) 1995-07-25

Similar Documents

Publication Publication Date Title
CA2114300C (en) Quinoline or quinazoline derivatives, their production and use
DE69528470T2 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
EP0634169B1 (en) Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
EP0567107B1 (en) Quinoline and quinazoline derivatives for treating arthritis
CZ280185B6 (cs) Deriváty benzimidazolu, způsob jejich přípravy a použití
US5650410A (en) Pharmaceutical composition containing quinoline or quinazoline derivatives and derivatives therefor
JP3917821B2 (ja) チエノピリジン誘導体、その製造法および用途
JP2646995B2 (ja) キノリンまたはキナゾリン誘導体およびそれらを含んでなる医薬
CN115667237A (zh) 作为bet抑制剂的新型杂环化合物
US6046189A (en) Thienopyridine derivatives and their use
US5641788A (en) Quinoline derivatives and pharmaceutical composition containing them
HK1011364A (en) Quinoline or quinazoline derivatives, their production and use
JPH0769890A (ja) キノリンまたはキナゾリン誘導体を含んでなる医薬組成物
JP2648434B2 (ja) キノリンまたはキナゾリン誘導体を含有する医薬組成物
JPH1059977A (ja) チエノピリジン誘導体およびそれらを含んでなる医薬
JPH08225577A (ja) チエノピリジンまたはチエノピリミジン誘導体およびそれらを含んでなる医薬
JPH09169734A (ja) 新規キノリン誘導体およびその製造法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed